Formulation of Amphotericin B in PEGylated Liposomes for Improved Treatment of Cutaneous Leishmaniasis by Parenteral and Oral Routes

MLA

Guilherme S. Ramos, et al. “Formulation of Amphotericin B in PEGylated Liposomes for Improved Treatment of Cutaneous Leishmaniasis by Parenteral and Oral Routes.” Pharmaceutics, vol. 14, no. 5, May 2022, p. 989. EBSCOhost, https://doi.org/10.3390/pharmaceutics14050989.

APA

Guilherme S. Ramos, Virgínia M. R. Vallejos, Gabriel S. M. Borges, Raquel M. Almeida, Izabela M. Alves, Marta M. G. Aguiar, Christian Fernandes, Pedro P. G. Guimarães, Ricardo T. Fujiwara, Philippe M. Loiseau, Lucas A. M. Ferreira, & Frédéric Frézard. (2022). Formulation of Amphotericin B in PEGylated Liposomes for Improved Treatment of Cutaneous Leishmaniasis by Parenteral and Oral Routes. Pharmaceutics, 14(5), 989. https://doi.org/10.3390/pharmaceutics14050989

Chicago

Guilherme S. Ramos, Virgínia M. R. Vallejos, Gabriel S. M. Borges, Raquel M. Almeida, Izabela M. Alves, Marta M. G. Aguiar, Christian Fernandes, et al. 2022. “Formulation of Amphotericin B in PEGylated Liposomes for Improved Treatment of Cutaneous Leishmaniasis by Parenteral and Oral Routes.” Pharmaceutics 14 (5): 989. doi:10.3390/pharmaceutics14050989.